ACS Pharmacotherapy Personalization Tool

ACS Pharmacotherapy Personalization Tool Explanation and Clinical Context This tool provides individualized pharmacotherapy recommendations for acute coronary syndrome based on AHA guideline twenty twenty five. Core therapy for all ACS patients includes rapid initiation of Aspirin P2Y12 inhibitor parenteral anticoagulation and high intensity statin therapy unless contraindicated. Dual antiplatelet therapy with Aspirin plus Ticagrelor or Prasugrel is preferred in PCI treated patients and Clopidogrel remains appropriate when fibrinolysis is used or bleeding risk is elevated.

Patients requiring long term anticoagulation such as atrial fibrillation generally receive oral anticoagulation with minimized antiplatelet exposure. Beta blocker and ACE inhibitor or ARB are fundamental after MI especially in left ventricular dysfunction heart failure hypertension or diabetes. MRA is beneficial post MI with LV dysfunction when renal function and potassium allow.

This tool is a clinical support reference and decision must integrate patient specific status hemodynamics renal function bleeding risk tolerance and comorbidity.